Halozyme Reaffirms Long-Term Royalty Growth Despite Proposed Medicare Pricing Changes
SAN DIEGO, June 15, 2026 Halozyme Therapeutics, Inc. has confirmed that it expects zero to minimal impact on royalty...
orphan drugs
Advertisement
Quoin Pharmaceuticals Expands QRX009 Topical Rapamycin Pipeline
ASHBURN, Va., April 28, 2026 Quoin Pharmaceuticals Ltd. has announced a major clinical and regulatory update for its QRX009...
Tenvie Therapeutics Doses First Patient in TNV262 Trial
Brisbane, California, USA, April 6, 2026 First-in-Human Study Targets Inflammation Pathways In a significant milestone for clinical-stage biotech innovation,...
Neurocrine Acquires Soleno to Boost Rare Disease Portfolio
San Diego & Redwood City, California, USA, April 6, 2026 Strategic Acquisition Strengthens Rare Disease Leadership In a major...
MIPLYFFA Real-World Data Strengthen NPC Treatment Impact
CELEBRATION, Fla., Feb. 4, 2026 —Zevra Therapeutics announced the presentation of positive new real-world data on MIPLYFFA® (arimoclomol) in...
Advertisements
Ultragenyx Gene Therapy Shows Durable Gains in MPS IIIA
NOVATO, Calif., February 3, 2026 — Ultragenyx Pharmaceutical Inc. has reported positive long-term clinical data for UX111, an investigational...
Advertisement
